| 000 | 01273 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250517113336.0 | ||
| 264 | 0 | _c20180126 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1940-6029 | ||
| 024 | 7 |
_a10.1007/978-1-4939-4011-0_13 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Zhiqiang | |
| 245 | 0 | 0 |
_aA Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations. _h[electronic resource] |
| 260 |
_bMethods in molecular biology (Clifton, N.J.) _c2016 |
||
| 300 |
_a149-57 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 |
_aBlast Crisis _xpathology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aDasatinib _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImatinib Mesylate _xpharmacology |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xgenetics |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 700 | 1 | _aChen, WenYong | |
| 773 | 0 |
_tMethods in molecular biology (Clifton, N.J.) _gvol. 1465 _gp. 149-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-1-4939-4011-0_13 _zAvailable from publisher's website |
| 999 |
_c26378167 _d26378167 |
||